FIELD: medicine.
SUBSTANCE: there are offered methods for determining therapeutic efficacy of insulin-like growth factor-1 receptor (IGF-1R) antagonists. The methods are based on detecting and counting the IGF-1R expressing circulating tumour cells.
EFFECT: invention can be used for screening and definition of a stage of a cancer, developing therapeutic regimens, monitoring of response to treatment and recurrent cancer.
12 cl, 4 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
| HEMOPOIETIC CELL CD34+ AND USE THEREOF | 2005 |
|
RU2390558C2 |
| USING MVA (MODIFIED VACCINIA ANKARA) FOR TREATING PROSTATE CANCER | 2008 |
|
RU2499606C2 |
| FOXM1 PEPTIDE AND MEDICINAL AGENT CONTAINING SAID PEPTIDE | 2008 |
|
RU2487886C2 |
| COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS | 2012 |
|
RU2641968C2 |
| PEPTIDES OBTAINED FROM p16 FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMOURS AND OTHER TUMOURS EXPRESSING p16 | 2012 |
|
RU2626542C2 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
| COMPOSITIONS AND METHODS FOR WT1-SPECIFIC IMMUNOTHERAPY | 1999 |
|
RU2237674C2 |
